-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Orchard Therapeutics plc (NASDAQ:ORTX) Receives Average Recommendation of "Hold" from Brokerages
Orchard Therapeutics plc (NASDAQ:ORTX) Receives Average Recommendation of "Hold" from Brokerages
Shares of Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) have received a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.
Separately, Barclays cut their price target on shares of Orchard Therapeutics from $6.00 to $4.00 in a research note on Friday, May 13th.
Get Orchard Therapeutics alerts:Institutional Trading of Orchard Therapeutics
A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in Orchard Therapeutics in the 4th quarter worth approximately $858,000. Harbor Capital Advisors Inc. purchased a new position in Orchard Therapeutics during the 4th quarter valued at $364,000. BlackRock Inc. raised its holdings in Orchard Therapeutics by 19.9% in the 1st quarter. BlackRock Inc. now owns 749,990 shares of the company's stock worth $534,000 after purchasing an additional 124,478 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Orchard Therapeutics in the 4th quarter worth about $141,000. Finally, Bank of America Corp DE boosted its stake in shares of Orchard Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 95,749 shares of the company's stock valued at $68,000 after purchasing an additional 54,270 shares in the last quarter. 56.47% of the stock is currently owned by hedge funds and other institutional investors.
Orchard Therapeutics Stock Performance
ORTX traded up $0.02 on Wednesday, hitting $0.61. The company's stock had a trading volume of 600 shares, compared to its average volume of 741,904. Orchard Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.18. The firm has a market cap of $77.14 million, a P/E ratio of -0.44 and a beta of 0.81. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.19. The company's 50 day simple moving average is $0.57 and its 200-day simple moving average is $0.69.Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). Orchard Therapeutics had a negative return on equity of 86.92% and a negative net margin of 1,452.46%. The company had revenue of $5.52 million during the quarter, compared to the consensus estimate of $4.97 million. Analysts forecast that Orchard Therapeutics will post -0.95 EPS for the current year.
Orchard Therapeutics Company Profile
(Get Rating)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Recommended Stories
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- Workhorse Group Is Ready To Get Back On The Horse
- A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- This Defense Stock Has Bullish Fundamentals AND Technicals
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) have received a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.
據MarketBeat.com報道，果園治療公司(納斯達克代碼：ORTX-GET評級)的股票已獲得目前覆蓋該股票的七家券商的共識評級為持有。一名分析師對該股的評級為賣出建議，兩名分析師發佈了持有建議，兩名分析師對該公司提出了買入建議。在去年更新了該股覆蓋範圍的經紀商中，平均12個月的價格目標是7.75美元。
Separately, Barclays cut their price target on shares of Orchard Therapeutics from $6.00 to $4.00 in a research note on Friday, May 13th.
另外，巴克萊在5月13日星期五的一份研究報告中將Orchard Treeutics的股票目標價從6.00美元下調至4.00美元。
Institutional Trading of Orchard Therapeutics
果園治療的機構性交易
A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in Orchard Therapeutics in the 4th quarter worth approximately $858,000. Harbor Capital Advisors Inc. purchased a new position in Orchard Therapeutics during the 4th quarter valued at $364,000. BlackRock Inc. raised its holdings in Orchard Therapeutics by 19.9% in the 1st quarter. BlackRock Inc. now owns 749,990 shares of the company's stock worth $534,000 after purchasing an additional 124,478 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Orchard Therapeutics in the 4th quarter worth about $141,000. Finally, Bank of America Corp DE boosted its stake in shares of Orchard Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 95,749 shares of the company's stock valued at $68,000 after purchasing an additional 54,270 shares in the last quarter. 56.47% of the stock is currently owned by hedge funds and other institutional investors.
多家機構投資者最近調整了對該公司的持股。SG America Securities LLC在第四季度購買了Orchard Treeutics的新股份，價值約85.8萬美元。港灣資本顧問公司在第四季度購買了Orchard Treeutics的一個新頭寸，價值36.4萬美元。貝萊德股份有限公司在第一季度增持了19.9%的果園治療公司的股份。貝萊德股份有限公司在上個季度增持了124,478股後，現在持有749,990股該公司股票，價值534,000美元。Acadian Asset Management LLC在第四季度購買了Orchard Treeutics的新股份，價值約14.1萬美元。最後，美國銀行DE在第一季度將其在Orchard Treeutics的股份增加了130.8%。美國銀行DE目前持有95,749股該公司股票，價值68,000美元，此前該公司在上一季度又購買了54,270股。56.47%的股票目前由對衝基金和其他機構投資者持有。
Orchard Therapeutics Stock Performance
果園治療公司股票表現
Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). Orchard Therapeutics had a negative return on equity of 86.92% and a negative net margin of 1,452.46%. The company had revenue of $5.52 million during the quarter, compared to the consensus estimate of $4.97 million. Analysts forecast that Orchard Therapeutics will post -0.95 EPS for the current year.
果園治療公司(納斯達克代碼：ORTX-GET評級)最近一次發佈財報是在5月12日(星期四)。該公司公佈本季度每股收益(0.35美元)，低於(0.25美元)和(0.10美元)的普遍預期。Orchard Treeutics的淨資產回報率為負86.92%，淨利潤率為負1452.46%。該公司本季度營收為552萬美元，而市場普遍預期為497萬美元。分析師預測，果園治療公司本年度的每股收益將達到0.95%。
Orchard Therapeutics Company Profile
果園治療公司簡介
(Get Rating)
(獲取評級)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Orchard Treateutics公司是一家生物製藥公司，在英國、歐盟和美國開發針對嚴重和危及生命的罕見疾病的基因療法。該公司的基因療法尋求將患者的造血幹細胞轉化為基因修飾的細胞藥物產品，通過單一給藥來治療患者的疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- Workhorse Group Is Ready To Get Back On The Horse
- A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- 免費獲取StockNews.com關於Orchard Treeutics(ORTX)的研究報告
- 工作馬集團準備重返賽馬
- DraftKings，Inc.的圓底開始逆轉
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎？
- 索菲金融股票終於準備好為投資者買單了嗎？
- 這隻國防股票的基本面和技術面都看漲
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《果園治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Orchard Treeutics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧